QI
KPTI icon

Qtron Investments’s Karyopharm Therapeutics KPTI Stock Holding History

Qtron Investments’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,222
Closed -$100K – 439
2022
Q3 		$100K Buy
+1,222
New +$91.3K 0.02% 401

Other funds holding KPTI

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Qtron Investments's KPTI Position: Q4 2022 in Review

Qtron Investments sold out of Karyopharm Therapeutics (KPTI) in Q4 2022, closing a stake of 1,222 shares — an estimated $100K sold.

Qtron Investments first reported a position in KPTI in Q3 2022 and held it in 1 quarter. The position peaked at $100K in Q3 2022. 154 funds tracked by Wall St. Rank hold KPTI as of Q4 2022.

  • Qtron Investments reported no remaining Karyopharm Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Qtron Investments sold 1,222 Karyopharm Therapeutics shares in Q4 2022, an estimated $100K.
  • Qtron Investments first reported a position in Karyopharm Therapeutics in Q3 2022 and held it in 1 quarter.
  • Qtron Investments's Karyopharm Therapeutics position peaked at $100K in Q3 2022.
  • 154 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2022.

Based on Qtron Investments's 13F filing for Q4 2022, filed 13 Feb 2023.